Form 4: Cerus Corp. Director Eric Bjerkholt Granted 60,000 Restricted Stock Units

Cerus Corp. Director Eric Bjerkholt was granted 60,000 Restricted Stock Units (RSUs) on June 3, 2025, increasing his beneficial ownership to 222,133 shares.

Summary

• Eric Bjerkholt, a Director of Cerus Corp. (CERS), acquired 60,000 shares of common stock on June 3, 2025.
• The acquisition was a grant of Restricted Stock Units (RSUs) under the Issuer's 2024 Equity Incentive Plan, with a transaction price of $0 per share.
• Each RSU represents a contingent right to receive one share of Cerus Corp. common stock.
• The RSUs are set to vest on the earlier of the first anniversary of the grant date or the day prior to the next annual meeting of stockholders, contingent on Mr. Bjerkholt's continuous service.
• Following this transaction, Eric Bjerkholt's total beneficial ownership in Cerus Corp. common stock increased to 222,133 shares.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns the director's interests with shareholders and indicates continued commitment, though it's a standard compensation event rather than a direct operational or financial achievement.

Positives

• The grant of 60,000 Restricted Stock Units to Director Eric Bjerkholt aligns his interests with those of shareholders, incentivizing long-term performance and retention.
• The transaction indicates continued commitment and engagement from a key board member.

Risks

• The issuance of RSUs, upon vesting, will result in a minor dilution of existing shareholder equity, although this is a standard practice for equity compensation plans.

Future Outlook

The granted RSUs are subject to a vesting schedule, which will occur on the earlier of the first anniversary of the grant date or the day prior to the next annual meeting of stockholders, provided the director maintains continuous service.

Industry Context

This Form 4 filing reflects a routine equity compensation event for a director, common across publicly traded companies, particularly in the biotechnology and medical device sectors where Cerus Corp. operates, to align executive and board interests with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation is a common practice in the biotechnology and healthcare industries, aligning with governance best practices for incentivizing long-term value creation.
• The vesting schedule, tied to continued service and annual meetings, is typical for such grants, similar to compensation structures seen at companies like Haemonetics Corporation (HAE) or Terumo Corporation (TYO:4543) for their non-executive directors.

Corporate Governance

Related Party Transactions

• The transaction involves a grant of equity compensation to a director, which is an insider transaction.

Stakeholder Impact

• Shareholders: Minor potential for future dilution upon RSU vesting, but also improved alignment of director interests with long-term company performance.
• Director (Eric Bjerkholt): Receives equity compensation, increasing his stake and incentivizing continued service.

Next Steps

• The granted RSUs will vest on the earlier of June 3, 2026 (first anniversary of grant) or the day prior to Cerus Corp.'s next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Cerus Corp, CERS, Form 4, SEC filing, insider transaction, Restricted Stock Units, RSUs, equity incentive plan, director compensation, beneficial ownership, stock grant